T here is growing evidence that sleep-disordered breathing can play a role in the progression of congestive heart failure (CHF) and that treating these breathing disorders in such patients can lead to improvements in cardiovascular outcomes. [1] [2] [3] A number of studies have reported that obstructive sleep apnea (OSA) and central sleep apnea (CSA) are very common and occur in Ϸ50% to 62% of patients with CHF. 4, 5 Both of these breathing disorders are associated with a Cheyne-Stokes pattern of periodic breathing with a waxing and waning of tidal volume (VT) during hyperpnea. In addition, owing to low cardiac output, lung-to-chemoreceptor circulatory delay and cycle length of periodic breathing are longer in CHF patients with sleep apnea than in patients with sleep apnea but normal cardiac function. 6 These observations suggest that in CHF patients, the periodic breathing cycle with or without upper airway obstruction is entrained by the prolonged circulation time.
Although there is usually a predominance of either OSA or CSA in CHF patients, both types may occur in the same individual. 4, 5 However, the reasons why OSA events occur at one time and CSA occur at another during the same night have not been examined. One factor that could be a determinant of apnea type is PCO 2 . In CHF patients, CSA is triggered by reductions in PCO 2 below the apneic threshold. 7, 8 In contrast, OSA is not associated with a fall in PaCO 2 . 5 Therefore, one would expect that CSA events would be associated with a lower PaCO 2 than OSA events.
In patients with CHF, PCO 2 is inversely proportional to pulmonary capillary wedge pressure. 9 Thus, hyperventilation in patients with CHF is probably due, in large measure, to stimulation of pulmonary vagal afferents by pulmonary congestion secondary to elevated left ventricular filling pressure. 9, 10 It has also been shown that while CHF patients are recumbent, cardiac output falls and left ventricular filling pressure rises overnight. 11 These tendencies could be aggravated by OSA, which can elevate pulmonary capillary wedge pressure 12 and reduce cardiac output. 13, 14 In view of these observations, we hypothesized that in patients with CHF in whom both OSA and CSA are present during the same night, minute ventilation (V I ) would be higher and PCO 2 lower during Cheyne-Stokes respiration with CSA than with OSA events. We further hypothesized that if CSA events are associated with an overnight deterioration in cardiac function, they would be more frequent at the end than at the beginning of the night and would be accompanied by longer circulation time than OSA events.
Methods

Subjects
Patients with CHF referred to the sleep laboratory were included in the study if they met the following criteria: (1) chronic CHF (left ventricular ejection fraction Ͻ40%) secondary to ischemic or idiopathic dilated cardiomyopathy, (2) chronic exertional dyspnea (NYHA class II or III), (3) appropriate pharmacological therapy for CHF, (4) stable clinical status as evidenced by an absence of acute exacerbations of dyspnea and edema or medication change for Ն1 month before entry, and (5) OSA coexisting with CSA on the same sleep study. The diagnosis of OSA coexisting with CSA was based on the presence of apneas and hypopneas occurring at a rate of Ն10 per hour of sleep, of which 15% to 85% had to be obstructive and the remainder central in nature. Exclusion criteria were a history of myocardial infarction, unstable angina, or cardiac surgery within 3 months of entry into the study. No patient was regularly taking alcohol or sedative medications. Alcohol, sedatives, and caffeinated beverages were not permitted during the 48 hours before the sleep studies. The protocol was approved by the Human Subjects Review Committee of the University of Toronto, and all patients gave written informed consent before participation.
Sleep Studies
Overnight sleep studies were performed in all subjects with the use of standard techniques. 15 Respiratory efforts and VT were recorded with a calibrated respiratory inductance plethysmograph (Respitrace, Ambulatory Monitoring, Inc). 15 Transcutaneous PCO 2 (PtcCO 2 ) was recorded with a transcutaneous capnograph (Kontron Medical). 7 Oxyhemoglobin saturation (SaO 2 ) was measured with an ear oximeter whenever a stable signal could be attained. When this was not possible, a finger oximeter was used.
CSAs and hypopneas were identified by the absence of a VT excursion for Ն10 seconds with no movements of the rib cage or abdomen. Central hypopneas were defined as a Ն50% reduction in VT from the baseline value, persisting for Ն10 seconds with proportional in-phase reductions in rib cage and abdominal movements. 6, 7 OSAs and hypopneas were similarly defined except that paradoxical thoracoabdominal motion had to be present throughout these events. Mixed apneas were defined as apneas that began with a central component and ended with an obstructive component. Because mixed apneas were initiated by a central component lasting Ն10 seconds that made up Ͼ50% of the apnea and because Ͻ15% of all events with a central component in each patient were mixed, mixed apneas were included as CSA events for the purpose of this study. The apnea-hypopnea index (AHI) was defined as the number of apneas and hypopneas per hour of sleep.
Statistical Analysis
V I was derived by multiplying mean VT by mean frequency for the ventilatory and apneic periods to give mean V I for the entire periodic breathing cycle. Mean PtcCO 2 and mean SaO 2 were calculated by averaging the high and low values for each 30-second epoch throughout the night. 7 In addition, the lowest SaO 2 and the percentage of OSA and CSA events in which SaO 2 fell below 90% were documented. Periodic breathing cycle length was measured 2 ways: from the beginning of inspiration of the first breath terminating one apnea to the onset of inspiration of the breath ending the next apnea from the VT signal, and as the time elapsed from one nadir in SaO 2 to the subsequent nadir. As an approximation of lung-to-carotid body circulatory delay, we measured lung-to-ear circulation time (LECT) as the time elapsed from the end of an apnea to the subsequent nadir of SaO 2 . 6 Similarly, in individuals in whom a finger oximeter was used, we measured lung-to-finger circulation time. Mean values of V I , PtcCO 2 , periodic breathing cycle length, circulation time, and, in those in whom an ear oximeter was used, LECT during periodic breathing with OSAs and CSAs were calculated by averaging data from 5 consecutive periodic breathing cycles with OSAs and 5 cycles with CSAs. These analyses were confined to stage 2 sleep to avoid any potential confounding influence of changes in sleep stage on breathing. In addition, the comparison of OSAs and CSAs was restricted to the same body position in each subject. Mean PtcCO 2 and the proportion of obstructive and central respiratory events occurring in the first and last quarters of the night were also determined.
Paired t tests were used to compare variables. Least-squares linear regression analysis was used to assess relationships between variables when appropriate. A value of PϽ0.05 was considered statistically significant. All results are expressed as meanϮSEM.
Results
Patient Characteristics
Twelve (11 men, 1 woman) of 65 CHF patients who underwent sleep studies in our laboratory over a 1-year period met our inclusion criteria. Their mean age was 62.5Ϯ2.2 years, and their body mass index was 27.6Ϯ1.0 kg/m 2 , indicating that they were generally not obese. The cause of CHF was coronary artery disease in 10 and idiopathic dilated cardiomyopathy in 2. Eight patients were in NYHA class II, and 4 were in class III. Severe left ventricular dysfunction was evidenced by a mean left ventricular ejection fraction of 28.4Ϯ3.2%. Medical therapy for CHF consisted of digoxin in 7, diuretics in 12, ACE inhibitors in 12, nitrates and/or hydralazine in 6, and ␤-blockers in 2 patients. Overnight polysomnographic data appear in the Table. The patients had a moderate frequency of respiratory events, as indicated by the AHI. There were relatively equal proportions of OSA and CSA events (range of OSA events was 27% to 84% and of CSA events was 16% to 73%). These events were accompanied by only mild O 2 desaturation.
Minute Ventilation, PtcCO 2 , and Circulation Time Figure 3 ).
Overnight Shift in Distribution of OSA and CSA Events
From the first to the last quarter of the night, there was a significant reduction in PtcCO 2 (PϽ0.01; Figure 4 ) accompanied by a shift in the proportion of OSA and CSA events from predominantly obstructive to predominantly central ( Figure  5 ). In none of these patients did we observe a shift from predominantly central to predominantly obstructive events 
Discussion
We have demonstrated in CHF patients having both OSAs and CSAs during the same night that OSA events predominate at the beginning and CSA events predominate at the end of the night. This overnight shift from OSA to CSA events was accompanied by reductions in PCO 2 resulting from increases in V I and by lengthening of circulation time. The close relationship between the overnight lengthening of circulation time and reductions in PCO 2 strongly suggests that the fall in PCO 2 and shift in apnea type are linked to an overnight deterioration in cardiac function. 6, 11, 16 Taken together, these findings suggest that in patients with CHF, overnight alterations in cardiac function influence both the lengths of the Cheyne-Stokes respiratory cycles and the nature of the apneas that occur in association with them. CSAs during sleep in patients with CHF are triggered by reductions in PCO 2 below the threshold for apnea. Inhalation of CO 2 abolishes them. 8 In addition, CHF patients with CSA have lower PCO 2 during sleep than either those with OSA or those without sleep apnea. 5 In patients with CSA, V I is higher and PtcCO 2 is lower during periods of recurrent CSAs than during regular breathing. 7 Therefore, the observation that the shift from OSA to CSA events was associated with an increase in V I and a decrease in PCO 2 is consistent with previous findings.
Three mechanisms could be involved in the overnight increase in V I , the decrease in PCO 2 , and the shift to more CSA: worsening hypoxia, increasing ventilatory responsiveness to CO 2 , and worsening of pulmonary congestion. 9, 16 Because there was no significant difference in the degree of hypoxia during OSA events at the beginning and CSA events at the end of the night, direct stimulation of ventilation by hypoxia is probably not the explanation for the overnight development of hypocapnia. Nevertheless, even mild degrees of intermittent hypoxia could increase sympathetic nervous activity and blood pressure and impair systolic and diastolic functions in the failing heart, thus contributing to overnight deterioration in cardiac function. [17] [18] [19] Javaheri 20 reported a significantly greater ventilatory response to CO 2 in CHF patients with CSA than in those without it. However, neither V I nor PCO 2 was assessed at night. In addition, it is more likely that recurrent apneas and arousals would cause an overnight decrease rather than an increase in the ventilatory response to CO 2 . 21 Thus, an overnight increase in ventilatory responsiveness to CO 2 probably does not account for the overnight decrease in PCO 2 . A more likely explanation is development of pulmonary congestion.
Increases in pulmonary venous pressure induce hyperventilation in animals through stimulation of pulmonary vagal afferents. 10 In addition, Solin et al 9 demonstrated that PaCO 2 is inversely related to pulmonary capillary wedge pressure in patients with CHF. Furthermore, CHF patients with CSA have higher pulmonary capillary wedge pressure than those without it. 9, 22 The frequency of CSA is directly related to left ventricular filling pressure. 9 Reductions in pulmonary capillary wedge pressure by medical therapy and continuous positive airway pressure diminish the frequency of central respiratory events. These data imply that hypocapnia and CSA are respiratory manifestations of elevated left ventricular filling pressures and pulmonary venous congestion.
Periodic breathing cycle length and LECT are inversely proportional to cardiac output. 6, 22 Accordingly, the most plausible explanation for the lengthening of the periodic breathing cycle and LECT from the beginning to the end of the night observed in the present study is an overnight fall in cardiac output. Although OSA events can be prolonged because of a delay in the onset of arousals that terminate them, such an effect cannot explain the longer cycle length of CSA than of OSA events. On the other hand, if we extrapolate from the data of Hall et al, 6 we can estimate that there was a reduction in cardiac output of Ϸ0.8 L/min related to the 2.5-second increase in circulatory delay from obstructive to central cycles. In CHF patients whose cardiac output is already low, such a further fall is liable to be clinically significant. Left ventricular volume could theoretically influence periodic breathing cycle length. However, we have no measures of left ventricular volume overnight. Moreover, we have previously shown that left ventricular end-diastolic volume influences periodic breathing cycle length only indirectly through its effect on cardiac output via Starling's Law. 22 Overnight reductions in PCO 2 were inversely proportional to overnight increases in LECT. These data suggest that an overnight reduction in cardiac output was accompanied by pulmonary congestion. 9 This concept is consistent with the findings of Gibbs et al, 11 who observed progressive overnight rises in pulmonary artery pressure in most patients with severe CHF. However, they provided no explanation for these overnight increases in pulmonary artery pressure. One possible explanation is an increase in venous return from the legs and abdomen while the patient is recumbent. Another possibility in patients such as ours is that OSAs at the beginning of the night contributed to overnight reductions in cardiac output and increases in left ventricular filling pressure.
In patients with OSA, cardiac output decreases and pulmonary artery wedge pressure increases during OSA events. 12, 13 These effects probably result from increases in left ventricular afterload caused by the effects of elevations in systemic blood pressures and exaggerated negative intrathoracic pressure during and immediately after OSAs. 23, 24 In a dog model of chronic OSA, Parker et al 25 made similar observations. They also found that over a 3-month period, these dogs developed increases in left ventricular mass and decreases in left ventricular ejection fraction. These data indicated that OSA can cause left ventricular hypertrophy and dysfunction.
Fletcher et al 16 also demonstrated that exposure of dogs to repetitive obstructive apneas for just 8 hours led to the development of interstitial pulmonary edema. These findings are compatible with case reports of acute nocturnal pulmonary edema in patients with OSA. 26 Furthermore, in patients with CHF, generation of negative intrathoracic pressure during simulated OSAs causes profound reductions in cardiac output in patients with either ischemic or idiopathic dilated cardiomyopathy. 14 In contrast, breath holds, which simulate the effects of CSAs, have no such effect. Taken together, these findings indicate that OSA can cause significant reductions in cardiac output and overnight development of pulmonary edema. CSAs appear less likely to do so.
The above findings suggest that in our patients with CHF, OSAs at the beginning of the night contributed to overnight reductions in cardiac output, as reflected by lengthening of circulation time 6 ; to pulmonary venous congestion, as reflected by increases in V I and reductions in PCO 2 ; and to the development of CSAs at the end of the night. To test these hypotheses directly, it would be necessary to perform overnight hemodynamic monitoring in such patients. Our findings also raise an intriguing question: Can OSA predispose to the development of CSA as cardiac function deteriorates over time in patients with CHF?
As shown in Figure 1 , both OSA and CSA events are associated with a Cheyne-Stokes ventilatory pattern. 24 These observations raise the possibility that both OSA and CSA are part of a spectrum of periodic breathing, which under some circumstances presents mainly as OSA and under others mainly as CSA. They are also compatible with the concept that in patients with CHF, central controller instability may entrain upper airway obstruction during the apneic portion of the Cheyne-Stokes respiratory cycle. 27 Alternatively, CHF may give rise to increased neck vein distension and upper airway edema that could narrow the upper airway and increase its collapsibility. 28 However, because such an effect is most likely to occur later in the night after prolonged recumbency, it would not explain the shift from OSA to CSA at the end of the night. Finally, it is also possible that in some of our patients, OSA preceded the onset of CHF and that this predisposed to the development of Cheyne-Stokes respiration and CSA. Our study was not designed to determine which of these proposed mechanisms was involved in the development of OSA events in our patients. It is likely that the degree to which each of these factors contributed to the development of OSA varied from individual to individual. Nevertheless, apnea type is dependent on PaCO 2 . If PaCO 2 remains above the apneic threshold, OSA events prevail; if it decreases below the threshold, CSA events prevail.
In conclusion, in some patients with CHF, both obstructive and central respiratory events occur during a single night and appear to represent extremes of a continuum of periodic breathing. Our findings further indicate that the overnight shift from OSA to CSA is related to reductions in PCO 2 caused by increases in V I . Most important, the close relationship between overnight reductions in PCO 2 and increases in circulatory delay suggests that the overnight shift in apnea type is linked to deterioration in cardiac function. This concept is consistent with the suggestion of Somers 29 that hemodynamic instability in patients with CHF may be related to instability in apnea type as well. Future acute studies with direct cardiac monitoring are needed to assess the potential role of OSAs in overnight worsening of heart function in patients with CHF. Our findings also imply that abolition of OSA would improve nocturnal hemodynamic function in patients with CHF. 24 
